ProCE Banner Activity

How to Approach Treatment of NTM Lung Disease

Clinical Thought

Here’s my summary of the nontuberculous mycobacterial (NTM) lung disease guideline and how it can help us overcome barriers to optimal outcomes in complex cases.

Released: September 29, 2023

Share

Faculty

Charles L. Daley

Charles L. Daley, MD

Professor of Medicine
Division of Mycobacterial and Respiratory Infections Department of Medicine
National Jewish Health
Denver, Colorado

Provided by

Provided by Clinical Care Options, LLC, produced in partnership with NTM Info & Research (NTMir). 

ProCE Banner

Supporters

Supported by an educational grant from Insmed Incorporated.

Insmed Incorporated

Partners

NTMIR

ProCE Banner

Faculty Disclosure

Primary Author

Charles L. Daley, MD

Professor of Medicine
Division of Mycobacterial and Respiratory Infections Department of Medicine
National Jewish Health
Denver, Colorado

Charles L. Daley, MD: consultant/advisor/speaker: AN2, AstraZeneca, Cepheid, Hyfe, Insmed, Lilly, Mannkind, Matinas BioPharma, NobHill, Otsuka, Spero Therapeutics, Zambon; researcher: AN2, Bugworks, Insmed, Juvabis, Paratek.